Adicet Bio, Inc. (NASDAQ: ACET) announced today the pricing of an underwritten registered direct offering. The offering includes 70,001,000 shares of common stock and 10,000,000 pre‑funded warrants to purchase common stock. It is a direct offering that allows the company to raise capital directly from investors.
The offering is expected to generate approximately $80 million in gross proceeds. These funds will be used to support ongoing clinical development programs and extend the company’s liquidity runway. The financing provides a critical source of capital for the company’s pipeline.
This financing event is significant for investors because it strengthens Adicet’s financial position and enables continued investment in its allogeneic gamma‑delta T cell therapy pipeline. The capital raise supports the company’s growth strategy and its ability to pursue clinical milestones. The event directly impacts the company’s ability to fund future development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.